April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Sergio Cifuentes: Reevaluation of HER2 status following T-DXd treatment
Mar 3, 2025, 11:35

Sergio Cifuentes: Reevaluation of HER2 status following T-DXd treatment

Sergio Cifuentes, Cancer Research Project Manager at CENEIT Mexico, shared a post on X about a paper by Mohamed Gouda et al. published in Clinical Cancer Research:

“Resistance to T-DXd:

  • HER2 loss: 32.4%
  • HER2 decrease expression: 29.4%

Reevaluation of HER2 status following T-DXd treatment should be considered prior to alternate HER2-targeted therapies.”

“Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer”

Authors: Mohamed Gouda, Amrit Gonugunta, Ecaterina Dumbrava, Hui Chen, Funda Meric-Bernstam et al.

Sergio Cifuentes: Reevaluation of HER2 status following T-DXd treatment

More posts featuring Sergio Cifuentes.